Table 1.
Baseline characteristics of the patients in cohort 1 and cohort 3
| Characteristic | Immunotherapy treated cohort (YTMA404) | Immunotherapy untreated cohort (YTMA250) | |
|---|---|---|---|
| All patients | Monotherapy and pretreatment specimens | ||
| Total quantified tumors | 69 | 56 | 258 |
| Type of immunotherapy | |||
| Single-agent anti-PD1/PD-L1 | 58 (84) | 56 (100) | |
| Anti-PD-1/PD-L1 + anti-CTLA4 | 9 (13) | 0 | |
| Chemotherapy + anti-PD-1/PD-L1 | 1 (1) | 0 | |
| Other combinations | 1 (1) | 0 | |
| Specimen type for biomarker assessment | |||
| Pre-immunotherapy | 62 (90) | 56 (100) | |
| Post-immunotherapy | 7 (10) | 0 | |
| Gender | |||
| Male | 38 (55) | 30 (54) | 106 (41) |
| Female | 31 (45) | 26 (46) | 131 (51) |
| *Missing | 21 | ||
| Age | |||
| < 70 yo | 35 (51) | 25 (45) | 132 (51) |
| >= 70 yo | 34 (49) | 31 (55) | 104 (40) |
| *Missing | 22 | ||
| ECOG performance status | |||
| 0 | 6 (9) | 5 (9) | |
| 1 | 54 (79) | 43 (77) | |
| 2 | 8 (12) | 7 (12) | |
| 3 | 1 (1) | 1 (2) | |
| Smoking history | |||
| Never smoker | 13 (19) | 10 (18) | 38 (15) |
| Current smoker | 16 (23) | 12 (21 | 62 (24 |
| Former smoker | 39 (56) | 33 (59) | 121 (47) |
| *Missing | 1 | 1 | 37 |
| Histology | |||
| Adenocarcinoma | 50 (72) | 41 (73) | 135 (52) |
| Squamous-cell carcinoma | 15 (22) | 12 (21) | 63 (24) |
| Large-cell carcinoma | 3 (4) | 3 (5) | 12 (5) |
| Others | 1 (1) | 24 (9) | |
| *Missing | 24 | ||
| Stage | |||
| I | 147 (57) | ||
| II | 45 (17) | ||
| III | 2 (3) | 2 (4) | 30 (11) |
| IV (M1a) | 18 (26) | 15 (27) | 10 (4) |
| IV (M1b) | 10 (14) | 9 (16) | |
| IV (M1c) | 39 (57) | 30 (54) | |
| *Missing | 26 | ||
| EGFR mutation status | |||
| Wild type | 44 (64) | 37 (66) | |
| Mutant | 9 (13) | 6 (11) | |
| *Missing | 16 | 13 | |
| KRAS mutation status | |||
| Wild type | 32 (46) | 25 (45) | |
| Mutant | 18 (23) | 15 (27) | |
| *Missing | 19 | 16 | |
| CNS metastasis | |||
| No | 50 (73) | 42 (75) | |
| Yes | 18 (26) | 13 (23) | |
| *Missing | 1 | 1 | |
| Liver metastasis | |||
| No | 56 (81) | 45 (80) | |
| Yes | 12 (17) | 10 (18) | |
| *Missing | 1 | 1 | |
| LIPI score | |||
| Good | 28 (41) | 22 (39) | |
| Intermediate | 26 (38) | 20 (36) | |
| Poor | 4 (6) | 4 (7) | |
| *Missing | 11 | 10 | |
| Prior therapies | 15 (22) | 9 (16) | |
| 0 | 34 (49) | 30 (54) | |
| 1 | 19 (27) | 16 (28) | |
| > 1 | 1 | 1 | |